Home LiteratureArticle Details
PMID: 12911847 Published · ppublish English Journal Article Review

Isoprenoid metabolism and the pleiotropic effects of statins.

Current atherosclerosis reports ·Vol. 5 ·No. 5 ·2003-09-00 ·Pages 372-8

Laufs U, Liao JK

Abstract

暂无摘要

MeSH Terms
Cardiovascular Diseases/drug therapy Cardiovascular System/drug effects,physiopathology Evaluation Studies as Topic Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology,therapeutic use Lipid Metabolism Mevalonic Acid/metabolism Polyisoprenyl Phosphates/metabolism Time Factors
Chemicals
Hydroxymethylglutaryl-CoA Reductase Inhibitors Polyisoprenyl Phosphates Mevalonic Acid
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Laufs Ulrich
Vascular Medicine Research, Brigham & Women's Hospital, 65 Landsdowne Street, Cambridge, MA 02139, USA.
Liao James K
References (58)
58 references, click to expand
  1. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.
    Circulation. 1999 Jul 20;100(3):230-5 PMID: 10411845
  2. Inhibition of proinflammatory cytokine production by pravastatin.
    Lancet. 1999 Mar 20;353(9157):983-4 PMID: 10459915
  3. Current perspectives on statins.
    Circulation. 2000 Jan 18;101(2):207-13 PMID: 10637210
  4. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Pharmacol Ther. 1999 Dec;84(3):413-28 PMID: 10665838
  5. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
    N Engl J Med. 2000 Mar 23;342(12):836-43 PMID: 10733371
  6. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
    Circulation. 2000 Jul 11;102(2):157-65 PMID: 10889125
  7. Targeting Rho in cardiovascular disease.
    Circ Res. 2000 Sep 29;87(7):526-8 PMID: 11009552
  8. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project.
    Circulation. 2001 Jan 23;103(3):387-92 PMID: 11157690
  9. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
    Mol Pharmacol. 2001 Mar;59(3):646-54 PMID: 11179461
  10. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
    Circulation. 2001 Jan 16;103(2):276-83 PMID: 11208689
  11. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
    Circulation. 2001 Mar 6;103(9):1191-3 PMID: 11238259
  12. Direct vascular effects of HMG-CoA reductase inhibitors.
    Trends Cardiovasc Med. 2000 May;10(4):143-8 PMID: 11239793
  13. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Am J Cardiol. 2001 Mar 8;87(5A):28B-32B PMID: 11256847
  14. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    JAMA. 2001 Apr 4;285(13):1711-8 PMID: 11277825
  15. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.
    J Am Coll Cardiol. 2001 Apr;37(5):1351-8 PMID: 11300446
  16. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
    N Engl J Med. 2001 Jun 28;344(26):1959-65 PMID: 11430324
  17. Statin-stimulated nitric oxide release from endothelium.
    Med Sci Monit. 2001 Jul-Aug;7(4):622-7 PMID: 11433186
  18. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.
    Circulation. 2001 Jul 24;104(4):376-9 PMID: 11468195
  19. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
    J Am Coll Cardiol. 2001 Nov 1;38(5):1581-3 PMID: 11691544
  20. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
    J Clin Invest. 2001 Nov;108(10):1429-37 PMID: 11714734
  21. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin).
    Am J Cardiol. 2001 Dec 1;88(11):1291-4 PMID: 11728357
  22. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.
    Am J Cardiol. 2001 Dec 1;88(11):1306-7 PMID: 11728362
  23. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study.
    Circulation. 2002 Jan 22;105(3):310-5 PMID: 11804985
  24. Cellular antioxidant effects of atorvastatin in vitro and in vivo.
    Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):300-5 PMID: 11834532
  25. Withdrawal of statins increases event rates in patients with acute coronary syndromes.
    Circulation. 2002 Mar 26;105(12):1446-52 PMID: 11914253
  26. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
    Cardiovasc Res. 2002 Mar;53(4):911-20 PMID: 11922901
  27. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Ann Pharmacother. 2002 May;36(5):751-7 PMID: 11978147
  28. Pleiotropic effects of HMG-CoA reductase inhibitors.
    Basic Res Cardiol. 2002 Mar;97(2):105-16 PMID: 12002257
  29. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
    Brain Res. 2002 Jun 28;942(1-2):23-30 PMID: 12031849
  30. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
    Lancet. 2002 Jul 6;360(9326):7-22 PMID: 12114036
  31. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.
    Circulation. 2002 Aug 20;106(8):1024-8 PMID: 12186811
  32. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.
    Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1452-8 PMID: 12231565
  33. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke.
    Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):156-7 PMID: 12588752
  34. Statin effects beyond lipid lowering--are they clinically relevant?
    Eur Heart J. 2003 Feb;24(3):225-48 PMID: 12590901
  35. Mechanisms of plaque stabilization with statins.
    Am J Cardiol. 2003 Feb 20;91(4A):4B-8B PMID: 12615292
  36. Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
    Am J Cardiol. 2003 Feb 20;91(4A):23B-29B PMID: 12615295
  37. Bile salt transporters: molecular characterization, function, and regulation.
    Physiol Rev. 2003 Apr;83(2):633-71 PMID: 12663868
  38. Statin-associated myopathy.
    JAMA. 2003 Apr 2;289(13):1681-90 PMID: 12672737
  39. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Lancet. 2003 Apr 5;361(9364):1149-58 PMID: 12686036
  40. Regulation of the mevalonate pathway.
    Nature. 1990 Feb 1;343(6257):425-30 PMID: 1967820
  41. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    N Engl J Med. 1990 Jul 26;323(4):224-8 PMID: 2114543
  42. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
    N Engl J Med. 1990 Jun 14;322(24):1700-7 PMID: 2342536
  43. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
    N Engl J Med. 1995 Nov 16;333(20):1301-7 PMID: 7566020
  44. Effect of pravastatin on outcomes after cardiac transplantation.
    N Engl J Med. 1995 Sep 7;333(10):621-7 PMID: 7637722
  45. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
    Lancet. 1994 Nov 19;344(8934):1383-9 PMID: 7968073
  46. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
    Am J Cardiol. 1994 May 26;73(14):3D-11D PMID: 8198021
  47. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
    N Engl J Med. 1996 Oct 3;335(14):1001-9 PMID: 8801446
  48. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
    Transplantation. 1996 Dec 15;62(11):1559-64 PMID: 8970607
  49. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
    Circulation. 1997 Jan 7;95(1):76-82 PMID: 8994420
  50. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.
    Circulation. 1997 Mar 4;95(5):1126-31 PMID: 9054840
  51. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
    Ann Pharmacother. 1997 Apr;31(4):489-91 PMID: 9101013
  52. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
    J Am Coll Cardiol. 1998 Mar 1;31(3):684-91 PMID: 9502654
  53. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
    Circulation. 1998 Apr 21;97(15):1440-5 PMID: 9576423
  54. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias.
    Arch Intern Med. 1998 Jun 8;158(11):1253-61 PMID: 9625405
  55. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
    Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5 PMID: 9671773
  56. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase.
    J Biol Chem. 1998 Sep 11;273(37):24266-71 PMID: 9727051
  57. Increased thrombotic vascular events after change of statin.
    Lancet. 1998 Dec 5;352(9143):1830-1 PMID: 9851392
  58. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.
    J Am Coll Cardiol. 1999 Jan;33(1):234-41 PMID: 9935036
Article Info
Journal
Current atherosclerosis reports
Abbr.
Curr Atheroscler Rep
ISSN
1523-3804
DOI
10.1007/s11883-003-0008-z
Published
2003-09-00
Pages
372-8
Language
English
Region
United States
NLM ID
100897685
PMCID
PMC2676316
Subset
IM
Grants
NINDS NIH HHS · P01 NS010828 · United States
NIDDK NIH HHS · R01 DK062729-01A1 · United States
NHLBI NIH HHS · R01 HL070274-02 · United States
NHLBI NIH HHS · P01 HL048743 · United States
NINDS NIH HHS · P01 NS010828-330036 · United States
NHLBI NIH HHS · R01 HL052233-05 · United States
NHLBI NIH HHS · R01 HL070274-01 · United States
NHLBI NIH HHS · R01 HL052233-07 · United States
NINDS NIH HHS · P50 NS010828 · United States
NHLBI NIH HHS · R01 HL052233-06 · United States
NHLBI NIH HHS · R01 HL052233 · United States
NIDDK NIH HHS · R01 DK062729 · United States
NHLBI NIH HHS · R01 HL070274 · United States
NINDS NIH HHS · P50 NS010828-290036 · United States
NHLBI NIH HHS · P01 HL048743-120008 · United States
External Links
PubMed source DOI: 10.1007/s11883-003-0008-z PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2